Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
3(50%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
1
17%
Ph phase_2
2
33%
Ph phase_1
3
50%

Phase Distribution

3

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
3(50.0%)
Phase 2Efficacy & side effects
2(33.3%)
Phase 3Large-scale testing
1(16.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

3

trials recruiting

Total Trials

6

all time

Status Distribution
Active(3)
Completed(2)
Other(1)

Detailed Status

Completed2
Active, not recruiting2
unknown1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
3
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (50.0%)
Phase 22 (33.3%)
Phase 31 (16.7%)

Trials by Status

completed233%
unknown117%
active_not_recruiting233%
recruiting117%

Recent Activity

3 active trials
Showing 5 of 6
active_not_recruitingphase_2

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

NCT06105619
recruitingphase_3

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

NCT05989542
active_not_recruitingphase_2

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

NCT04258033
unknownphase_1

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

NCT05367388
completedphase_1

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

NCT02978261
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT06105619Phase 2

A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN).

Active Not Recruiting
NCT05989542Phase 3

A Confirmatory Clinical Study in NSCLC Patients With MET Exon 14 Mutation (KUNPENG-2)

Recruiting
NCT04258033Phase 2

A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)

Active Not Recruiting
NCT05367388Phase 1

A Study Comparing Two Different Capsules, APL-101 and PLB-1001 Capsules, in Healthy Chinese and Caucasian Participants

Unknown
NCT02978261Phase 1

Study of a c-Met Inhibitor PLB1001 in Patients With PTPRZ1-MET Fusion Gene Positive Recurrent High-grade Gliomas

Completed
NCT02896231Phase 1

First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001

Completed

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6